We read with great interest the article by Kilburn et al. [1], which aimed to describe the prevalence of comorbidities in individuals with facioscapulohumeral muscular dystrophy (FSHD) using data from the MD STARnet. Although this study offers valuable epidemiological data, several aspects warrant further clarification and expansion to enhance the understanding of comorbidities in FSHD. A major limitation of this study is the lack of consideration for other comorbidities.
